<DOC>
	<DOCNO>NCT00397943</DOCNO>
	<brief_summary>This study ass safety immunogenicity 2 different formulation tuberculosis vaccine GSK692342 healthy adult .</brief_summary>
	<brief_title>Safety Immunogenicity 2 Formulations Tuberculosis Vaccine GSK692342 Given 0,1 Months Healthy Adults</brief_title>
	<detailed_description>The study design vaccination phase ( include screening , 2 dos vaccine 1 month apart follow-up 1 month post dose 2 ) , perform observer blind manner . This follow 3 year follow-up continue open manner . No new subject recruit follow-up phase . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol A male female , include , 18 50 year age time first vaccination . Written inform consent obtain subject prior study procedure . Free obvious health problem establish medical history clinical examination enter study . Subjects must PPD negative skin reactivity ( 0 mm induration 48 72 hour PPD skin test administration ) . Clinically normal laboratory value creatinine , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , complete blood count ( CBC ) differential , haemoglobin , platelet count urinalysis . Seronegative human immunodeficiency virus1 2 ( HIV 1/2 ) antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibodies If subject female , must nonchildbearing potential , , childbearing potential , must abstinent use adequate contraceptive precaution 30 day prior vaccination , negative pregnancy test must agree continue precaution two month completion vaccination series . No evidence pulmonary pathology ( i.e . acute chronic pulmonary disease ; past TB infection/disease ) confirm chest Xray . History previous exposure experimental product contain component experimental vaccine . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within 6 month prior first vaccine dose . Any chronic drug therapy continue study period . Vitamins and/or dietary supplement , herbal medication , birth control pill , antihistamine seasonal allergy , SSRIs ( e.g . Prozac , Zoloft , Paxil ) , NSAIDs ( nonsteroidal antiinflammatory drug e.g . aspirin , ibuprofen ) , acetaminophen allow . History document exposure Mycobacterium tuberculosis . History prior vaccination experimental Mycobacterium tuberculosis vaccine . Administration immunoglobulins , immunotherapy and/or blood product within 3 month precede first dose study vaccination , plan administration study period . Participation another experimental protocol study period . Any confirm suspected immunosuppressive immunodeficient condition ; family history congenital hereditary immunodeficiency . History hypersensitivity vaccine vaccine component History acute chronic illness medication , opinion investigator , may interfere evaluation safety immunogenicity vaccine . Volunteers personal history autoimmune disease describe firstdegree relative clearly document autoimmune disease . History neurological disorder seizure . History chronic alcohol consumption and/or drug abuse . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect . Pregnant female , lactate female female planning become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Tuberculosis</keyword>
</DOC>